SCHEMBL7184065

SCHEMBL7184065

COc1cc(OC)c(C(=O)[P](=O)c2ccccc2C(=O)c2c(Cl)cc(Cl)cc2Cl)c(OC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.41
ABCG2 Q9UNQ0 3/20 0.40
MAPT P10636 5/20 0.40
RAB9A P51151 1/20 0.40
LMNA P02545 1/20 0.38
KDM4E B2RXH2 1/20 0.37
RORC P51449 1/20 0.37
RORB Q92753 1/20 0.37
POLB P06746 1/20 0.36
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
CYP3A4 P08684 2/20 0.36
TP53 P04637 1/20 0.36
ATM Q13315 1/20 0.36
HSD17B10 Q99714 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
USP2 O75604 1/20 0.35
MAPK1 P28482 1/20 0.35
ELANE P08246 1/20 0.35
MAOA P21397 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7175462 0.92 KMT2A (0.45) KMT2AABCG2MAPTLMNARORC
SCHEMBL7177554 0.92 LMNA (0.39) KMT2ARAB9ALMNAKDM4ERORC
SCHEMBL7178126 0.88 KMT2A (0.41) KMT2AABCG2MAPTRAB9ALMNA
SCHEMBL7182505 0.88 KMT2A (0.40) KMT2AABCG2MAPTRAB9ALMNA
SCHEMBL7180936 0.87 KMT2A (0.40) KMT2AABCG2MAPTRAB9ALMNA
SCHEMBL7182106 0.87 KMT2A (0.45) KMT2AABCG2MAPTLMNAPOLB
SCHEMBL7188977 0.85 MAPT (0.41) KMT2AABCG2MAPTRAB9APOLB
SCHEMBL7181292 0.84 ALDH1A1 (0.38) KMT2AABCG2MAPTRAB9ALMNA
SCHEMBL7736110 0.83 ALDH1A1 (0.43) KMT2AABCG2MAPTRAB9APOLB
SCHEMBL7186470 0.83 RORC (0.42) KMT2ARAB9ALMNARORCCES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KMT2A 1586/4885ABCG2 3732/4885MAPT 4870/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KMT2A 956/4885ABCG2 4323/4885MAPT 4859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.